An aminopyridine compound that inhibits JNK1, JNK2, and JNK3 (Kis = 2, 4, and 52 nM, respectively) inhibits the phosphorylation of the JNK substrate c-Jun in HepG2 cells (EC<sub>50</sub> = 920 nM).
An aminopyridine compound that inhibits JNK1, JNK2, and JNK3 (Kis = 2, 4, and 52 nM, respectively) inhibits the phosphorylation of the JNK substrate c-Jun in HepG2 cells (EC<sub>50</sub> = 920 nM).
Lavendustin A is a selective inhibitor of epidermal growth factor (EGF) receptor-associated tyrosine kinase (IC<sub>50</sub> = 11 nM) that was first isolated from a Streptomyces culture filtrate. It does not inhibit protein kinase A (PKA), PKC, or
Lavendustin A is a selective inhibitor of epidermal growth factor (EGF) receptor-associated tyrosine kinase (IC<sub>50</sub> = 11 nM) that was first isolated from a Streptomyces culture filtrate. It does not inhibit protein kinase A (PKA), PKC, or
A positive modulator of the Wnt/&beta-catenin pathway, as it augments Wnt-mediated signaling in cells at concentrations of 5 to 20 µM active in vivo, altering Wnt-dependent gene expression and embryonic development in zebrafish.
A positive modulator of the Wnt/&beta-catenin pathway, as it augments Wnt-mediated signaling in cells at concentrations of 5 to 20 µM active in vivo, altering Wnt-dependent gene expression and embryonic development in zebrafish.
A cell-impermeant, water-soluble tetrazolium salt used for assessing cell metabolic activity is reduced by NADH to a water-soluble formazan dye with absorbance max at 460 nm.
A cell-impermeant, water-soluble tetrazolium salt used for assessing cell metabolic activity is reduced by NADH to a water-soluble formazan dye with absorbance max at 460 nm.
An orally-available drug that has shown promise in the treatment of neurodegenerative diseases, including Alzheimer&rsquos disease and Huntington&rsquos disease.
An orally-available drug that has shown promise in the treatment of neurodegenerative diseases, including Alzheimer&rsquos disease and Huntington&rsquos disease.
A selective, irreversible JNK inhibitor (IC<sub>50</sub>s = 4.67, 18.7, and 0.98 nM for JNK1, 2, and 3, respectively) prevents phosphorylation of c-Jun in A375 and HeLa cells (EC<sub>50</sub>s = 338 and 486 nM, respectively).
A selective, irreversible JNK inhibitor (IC<sub>50</sub>s = 4.67, 18.7, and 0.98 nM for JNK1, 2, and 3, respectively) prevents phosphorylation of c-Jun in A375 and HeLa cells (EC<sub>50</sub>s = 338 and 486 nM, respectively).
An ATP-competitive inhibitor of JNK1, JNK2, and JNK3 (IC<sub>50</sub>s = 150, 220, and 70 nM, respectively) effective in vivo in gerbils, mice, and rats via oral, intravenous, or intraperitoneal administration.
An ATP-competitive inhibitor of JNK1, JNK2, and JNK3 (IC<sub>50</sub>s = 150, 220, and 70 nM, respectively) effective in vivo in gerbils, mice, and rats via oral, intravenous, or intraperitoneal administration.
A cell-permeable antagonist of calmodulin (Ki = 11 &muM) also associates, at lower affinities, with calcium-binding domains of other proteins, including troponin C and myosin light chain kinase (Ki = 70 and 300 &muM, respectively).
A cell-permeable antagonist of calmodulin (Ki = 11 &muM) also associates, at lower affinities, with calcium-binding domains of other proteins, including troponin C and myosin light chain kinase (Ki = 70 and 300 &muM, respectively).